drugset

drugset / Trial / NCT05323812

ASURE: Alzheimer Study Using oRal Edaravone

NCT05323812 ↗

Phase 2 Completed 61 enrolled Treeway B.V.

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a multi-center, Phase IIa, randomized, double-blind, placebo-controlled study in patients with Alzheimer's Disease (AD).

Timeline

Start: 2023-03-01
Primary completion: 2024-12-30
Completion: 2024-12-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Edaravone	Unknown	100 mg	—

Indications